This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karp, J. E. Articles by Colevas, A. D. Search for Related Content PubMed PubMed Citation Articles by Karp, J. E. Articles by Colevas, A. D.

Timed Sequential Therapy of Acute Leukemia with Flavopiridol

In Vitro Model for a Phase I Clinical Trial¹

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201 [J. E. K., D. D. R., W. Y., M. L. T., Y. W., J. G., D. L. M., T. N.]; Baltimore Veterans Administration Medical Center, Baltimore, Maryland [D. D. R.]; and Investigational Drug Branch, Clinical Trials Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute [J. J. W., A. D. C.], Bethesda, Maryland

Purpose: The survival of adults with acute leukemias remains unsatisfactory and requires new treatment approaches. Flavopiridol modulates cell cycle progression, inhibits transcription, and induces apoptosis. We designed an in vitro model of timed sequential therapy for acute leukemia to determine whether flavopiridol can: (a) trigger apoptosis in fresh acute leukemia; and (b) recruit surviving leukemic cells to a proliferative state, thereby priming such cells for the S-phase-related cytotoxicity of 1-ß-D-arabinofuranosylcytosine (ara-C).

Experimental Design: Bone marrow cells from 20 adults with relapsed and refractory acute leukemias were enriched for blasts by Ficoll Hypaque sedimentation. Blasts were cultured on day 0 in flavopiridol 250 nM for 24 h, removed from flavopiridol for 24 h, and then cultured in ara-C 1 µM for an additional 72 h (F₂₅₀A₁). Apoptosis and cell cycle phase distribution were estimated from cells stained with propidium iodide. Cell survival was determined after the 72 h ara-C exposure by double cytofluorescence assay with fluorescein diacetate and propidium iodide.

Results: Flavopiridol induced a 4.3-fold increase in apoptosis in human leukemia samples within the first 24 h of culture. Subsequent removal of flavopiridol led to a 1.7-fold increase in the proportion of cells in S phase by day 2. Mean survival in F₂₅₀A₁ cultures after 72 h exposure to ara-C was 35.6% compared with flavopiridol alone (F₂₅₀A₀, 56.1%; P = 0.0003) and ara-C alone (F₀A₁, 65.2%; P < 0.00001).

Conclusions: Flavopiridol induces apoptosis in marrow blasts from patients with refractory acute leukemias. Furthermore, flavopiridol pretreatment increases the proapoptotic and cytotoxic effects of ara-C. The advantage of sequential FP₂₅₀A₁ over either agent alone is seen for both acute myelogenous leukemia and acute lymphoblastic leukemia. These findings support a clinical trial of timed sequential therapy where flavopiridol is given for cytoreduction and subsequent priming of remaining leukemic cells for enhanced cycle-dependent drug cytotoxicity.

This article has been cited by other articles:

				Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells Mol. Pharmacol., May 1, 2008; 73(5): 1549 - 1557. [Abstract] [Full Text] [PDF]

				J. E. Karp, B. D. Smith, M. J. Levis, S. D. Gore, J. Greer, C. Hattenburg, J. Briel, R. J. Jones, J. J. Wright, and A. D. Colevas Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia Clin. Cancer Res., August 1, 2007; 13(15): 4467 - 4473. [Abstract] [Full Text] [PDF]

				J. E. Karp, A. Passaniti, I. Gojo, S. Kaufmann, K. Bible, T. S. Garimella, J. Greer, J. Briel, B. D. Smith, S. D. Gore, et al. Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-{beta}-D-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias Clin. Cancer Res., December 1, 2005; 11(23): 8403 - 8412. [Abstract] [Full Text] [PDF]

				J. E. Karp, B. D. Smith, J. Greer, J. Briel, M. J. Levis, M. A. McDevitt, S. D. Gore, and A. D. Colevas Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 2784 - 2784. [Abstract]

				Y. Takada and B. B. Aggarwal Flavopiridol Inhibits NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation: ABROGATION OF CYCLIN D1, CYCLOOXYGENASE-2, AND MATRIX METALLOPROTEASE-9 J. Biol. Chem., February 6, 2004; 279(6): 4750 - 4759. [Abstract] [Full Text] [PDF]

				T. Nakanishi, J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei, and D. D. Ross Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients Clin. Cancer Res., August 1, 2003; 9(9): 3320 - 3328. [Abstract] [Full Text] [PDF]